High-throughput, in-depth and estimated absolute quantification of plasma proteome using data-independent acquisition/mass spectrometry ("HIAP-DIA")
- PMID: 33460299
- DOI: 10.1002/pmic.202000264
High-throughput, in-depth and estimated absolute quantification of plasma proteome using data-independent acquisition/mass spectrometry ("HIAP-DIA")
Abstract
Mass spectrometry-based plasma proteomics has been demonstrated to be a useful tool capable of quantifying hundreds of proteins in a single LC-MS/MS experiment, for biomarker discovery or elucidation of disease mechanisms. We developed a novel data-independent acquisition (DIA)/MS-based workflow for high-throughput, in-depth and estimated absolute quantification of plasma proteins (termed HIAP-DIA), without depleting high-abundant proteins, in a single-shot experiment. In HIAP-DIA workflow, we generated an ultra-deep cumulative undepleted and depleted spectral library which contained 55,157 peptides and 5,328 proteins, optimized column length (50 cm) and gradient (90 min) of liquid chromatography instrumentation, optimized 50 DIA segments with average isolation window 17 Th, and selected reference proteins for estimated absolute quantification of all plasma proteins. A total of 606 proteins were quantified in triplicate, and 427 proteins were quantified with CV <20% in plasma proteome. R-squared value of overlapped 208 endogenous PQ500 estimated protein amounts from HIAP-DIA and absolute quantification with internal standards was 0.82, indicating high quantification accuracy of HIAP-DIA. As a pilot study, the HIAP-DIA approach described here was applied to a myelodysplastic syndromes (MDS) disease cohort. We achieved absolute quantification of 789 plasma proteins in 22 clinical plasma samples, spanning less than six orders of magnitude with quantification limit 10-20 ng/mL, and discovered 95 differentially expressed proteins providing insights into MDS pathophysiology.
Keywords: Orbitrap; data-independent acquisition; myelodysplastic syndromes; plasma proteomics; quantitative proteomics.
© 2021 Wiley-VCH GmbH.
Similar articles
-
Reproducibility, Specificity and Accuracy of Relative Quantification Using Spectral Library-based Data-independent Acquisition.Mol Cell Proteomics. 2020 Jan;19(1):181-197. doi: 10.1074/mcp.RA119.001714. Epub 2019 Nov 7. Mol Cell Proteomics. 2020. PMID: 31699904 Free PMC article.
-
Quantitative Proteomics Based on Optimized Data-Independent Acquisition in Plasma Analysis.J Proteome Res. 2017 Feb 3;16(2):665-676. doi: 10.1021/acs.jproteome.6b00727. Epub 2017 Jan 3. J Proteome Res. 2017. PMID: 27995795 Free PMC article.
-
Optimization of Data-Independent Acquisition Mass Spectrometry for Deep and Highly Sensitive Proteomic Analysis.Int J Mol Sci. 2019 Nov 26;20(23):5932. doi: 10.3390/ijms20235932. Int J Mol Sci. 2019. PMID: 31779068 Free PMC article.
-
Recent Developments in Data Independent Acquisition (DIA) Mass Spectrometry: Application of Quantitative Analysis of the Brain Proteome.Front Mol Neurosci. 2020 Dec 23;13:564446. doi: 10.3389/fnmol.2020.564446. eCollection 2020. Front Mol Neurosci. 2020. PMID: 33424549 Free PMC article. Review.
-
Technical advances in proteomics: new developments in data-independent acquisition.F1000Res. 2016 Mar 31;5:F1000 Faculty Rev-419. doi: 10.12688/f1000research.7042.1. eCollection 2016. F1000Res. 2016. PMID: 27092249 Free PMC article. Review.
Cited by
-
An overview of technologies for MS-based proteomics-centric multi-omics.Expert Rev Proteomics. 2022 Mar;19(3):165-181. doi: 10.1080/14789450.2022.2070476. Epub 2022 May 2. Expert Rev Proteomics. 2022. PMID: 35466851 Free PMC article.
-
Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson's Disease.Int J Mol Sci. 2022 Aug 18;23(16):9299. doi: 10.3390/ijms23169299. Int J Mol Sci. 2022. PMID: 36012563 Free PMC article. Review.
-
Assessment of a 60-Biomarker Health Surveillance Panel (HSP) on Whole Blood from Remote Sampling Devices by Targeted LC/MRM-MS and Discovery DIA-MS Analysis.Anal Chem. 2023 Jul 25;95(29):11007-11018. doi: 10.1021/acs.analchem.3c01189. Epub 2023 Jun 30. Anal Chem. 2023. PMID: 37389440 Free PMC article.
References
REFERENCES
-
- Füzéry, A. K., Levin, J., Chan, M. M., & Chan, D. W. (2013). Translation of proteomic biomarkers into FDA approved cancer diagnostics: Issues and challenges. Clinical Proteomics, 10(1), 13.
-
- Végvári, Á., Welinder, C., Lindberg, H., Fehniger, T. E., & Marko-Varga, G. (2011). Biobank resources for future patient care: developments, principles and concepts. Journal of Clinical Bioinformatics, 1(1), 24.
-
- Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017). Revisiting biomarker discovery by plasma proteomics. Molecular Systems Biology, 13(9), 942.
-
- Geyer, P. E., Kulak, N. A., Pichler, G., Holdt, L. M., Teupser, D., & Mann, M. (2016). Plasma proteome profiling to assess human health and disease. Cell Systems, 2(3), 185-195.
-
- Niu, L., Geyer, P. E., Wewer Albrechtsen, N. J., Gluud, L. L., Santos, A., Doll, S., Treit, P. V., Holst, J. J., Knop, F. K., Vilsbøll, T., Junker, A., Sachs, S., Stemmer, K., Müller, T. D., Tschöp, M. H., Hofmann, S. M., & Mann, M. (2019). Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Molecular Systems Biology, 15(3), e8793.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous